I've just started at <a href="http://www.reterefit.com/index.php/eyelastin-reviews-aed1.pdf">eyelastin reviews</a> FMC, a New York-based investment advisory firm with a 9.9percent stake in Vivus, has repeatedly criticized the company, saying it badly mishandled the launch of its obesity drug Qsymiaand failed to land a large company partner with deep pockets anda big enough sales force to help the drug reach its blockbusterpotential.